Du B, Qiu H B, Zhan X, Wang Y S, Kang H Y J, Li X Y, Wang F, Sun B, Tong Z H
Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 14;43(0):E012. doi: 10.3760/cma.j.issn.1001-0939.2020.0012.
The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (12 mg.kg(-1).d(-1), 35d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.
新型冠状病毒肺炎（NCP，世界卫生组织于2020年2月11日将其命名为COVID-19，自那时起在中国引发了严重的突发公共卫生事件。截至本稿件提交时，确诊病例数已超过4万例。冠状病毒在全球范围内引发了多次疫情，但由2019新型冠状病毒引起的当前传染病爆发程度空前。已发表的关于2019新型冠状病毒（n-Cov）的队列研究均为单中心研究或回顾性研究。我们在此分享新型冠状病毒肺炎治疗的经验并进行文献综述。鉴于利巴韦林和α干扰素对中东呼吸综合征（MERS）的疗效，国家卫生健康委第5版诊疗方案（修订版）推荐二者联合使用；鉴于新型冠状病毒肺炎尚无特效抗病毒药物，洛匹那韦/利托那韦和瑞德西韦的有效性需要通过随机对照试验（RCT）来证实。国家卫生健康委第5版诊疗方案（修订版）推荐短期使用全身性糖皮质激素（12 mg·kg⁻¹·d⁻¹，35天），但其有效性仍有待RCT证实。应避免不恰当使用抗生素，尤其是联合使用广谱抗生素，因为新型冠状病毒肺炎通常不会合并细菌感染。
